Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence

Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyz...

ver descrição completa

Detalhes bibliográficos
Autores: Pérez Calahorra, Sofía, Laclaustra, Martín, Marco Benedi, Victoria, Pintó Sala, Xavier, Sánchez Hernández, Rosa M., Plana, Núria, Ortega Martínez de Victoria, Emilio, Fuentes, Francisco, Civeira, Fernando
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/173828
Acesso em linha:https://hdl.handle.net/2445/173828
Access Level:acceso abierto
Palavra-chave:Malalties cardiovasculars
Aterosclerosi
Cardiovascular diseases
Atherosclerosis
id ES_e2a0fc22138550f2ee769a417bbbd74d
oai_identifier_str oai:recercat.cat:2445/173828
network_acronym_str ES
network_name_str España
repository_id_str
spelling Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrencePérez Calahorra, SofíaLaclaustra, MartínMarco Benedi, VictoriaPintó Sala, XavierSánchez Hernández, Rosa M.Plana, NúriaOrtega Martínez de Victoria, EmilioFuentes, FranciscoCiveira, FernandoMalalties cardiovascularsAterosclerosiCardiovascular diseasesAtherosclerosisBackground: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.BioMed Central2021202120192021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion6 p.application/pdfhttps://hdl.handle.net/2445/173828Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1186/s12944-019-1153-xLipids in Health and Disease, 2019, vol. 18https://doi.org/10.1186/s12944-019-1153-xcc by (c) Pérez Calahorra et al., 2019http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1738282026-05-29T05:05:01Z
dc.title.none.fl_str_mv Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
title Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
spellingShingle Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
Pérez Calahorra, Sofía
Malalties cardiovasculars
Aterosclerosi
Cardiovascular diseases
Atherosclerosis
title_short Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
title_full Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
title_fullStr Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
title_full_unstemmed Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
title_sort Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
dc.creator.none.fl_str_mv Pérez Calahorra, Sofía
Laclaustra, Martín
Marco Benedi, Victoria
Pintó Sala, Xavier
Sánchez Hernández, Rosa M.
Plana, Núria
Ortega Martínez de Victoria, Emilio
Fuentes, Francisco
Civeira, Fernando
author Pérez Calahorra, Sofía
author_facet Pérez Calahorra, Sofía
Laclaustra, Martín
Marco Benedi, Victoria
Pintó Sala, Xavier
Sánchez Hernández, Rosa M.
Plana, Núria
Ortega Martínez de Victoria, Emilio
Fuentes, Francisco
Civeira, Fernando
author_role author
author2 Laclaustra, Martín
Marco Benedi, Victoria
Pintó Sala, Xavier
Sánchez Hernández, Rosa M.
Plana, Núria
Ortega Martínez de Victoria, Emilio
Fuentes, Francisco
Civeira, Fernando
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties cardiovasculars
Aterosclerosi
Cardiovascular diseases
Atherosclerosis
topic Malalties cardiovasculars
Aterosclerosi
Cardiovascular diseases
Atherosclerosis
description Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.
publishDate 2019
dc.date.none.fl_str_mv 2019
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173828
url https://hdl.handle.net/2445/173828
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/s12944-019-1153-x
Lipids in Health and Disease, 2019, vol. 18
https://doi.org/10.1186/s12944-019-1153-x
dc.rights.none.fl_str_mv cc by (c) Pérez Calahorra et al., 2019
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Pérez Calahorra et al., 2019
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6 p.
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422427636760576
score 15.81155

Registos relacionados